Clinical Trial Update: Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating a dendritic cell tumor fusion vaccine with GM-CSF in renal cell carcinoma; results were posted after completion in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Dendritic cell/tumor fusion vaccine
• sargramostim (sargramostim)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Renal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-02-17